Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Bob who wrote (224)	5/18/1998 10:26:00 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 496

One of the reasons I have continued to recommend GLFD in spite of the disappointment around Gliadel sales and the neuroimmunophilin pace of development is the prospect of another corporate alliance: both NAALADase and PARP are being offered to suitors. NAALADase, because of its presynaptic 'upstream' approach to stroke/trauma neurotoxicity, would be my personal favorite for a partnership this year. A third but less exciting collaborative option is the semi-revived Dopascan program. I agree that one 'ace' that GLFD always possesses is the quality of the discovery research, but it is difficult to quantify that value in any particular timeframe. NeuroInvestment (www.neuroinv.com)